The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Advanced Proteome Therapeutics Announces Anti-Cancer R&D Gathers Momentum
Jan. 31, 2018 08:54AM PST
Biotech InvestingAdvanced Proteome Therapeutics (TSXV:APC) announces that during the 2017 calendar year, it has witnessed very significant progress in APC’s scientific program that has bolstered opportunities for achieving commercial success. As quoted in the press release: As we gather momentum and follow through with next steps in 2018, the Company is poised to obtain several key results …
Advanced Proteome Therapeutics (TSXV:APC) announces that during the 2017 calendar year, it has witnessed very significant progress in APC’s scientific program that has bolstered opportunities for achieving commercial success.
As quoted in the press release:
As we gather momentum and follow through with next steps in 2018, the Company is poised to obtain several key results from the testing of novel ADCs in animal studies. Technology transfer and scale-up of the conjugation technology by our contractual partners for animal testing of several therapeutically validated antibodies and their evaluation as potential ADC products have begun at the National Research Council of Canada (News releases-July18, 2017; November 20, 2017.
Outlook Reports
Featured Biotech Investing Stocks
Browse Companies
MARKETS
COMMODITIES
| Commodities | |||
|---|---|---|---|
| Gold | 2334.55 | +18.25 | |
| Silver | 27.43 | +0.25 | |
| Copper | 4.56 | +0.07 | |
| Oil | 83.77 | +0.96 | |
| Heating Oil | 2.57 | +0.01 | |
| Natural Gas | 1.59 | -0.06 | |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.